MX2023010606A - Formas de sales y sólidas de un inhibidor de cinasas. - Google Patents
Formas de sales y sólidas de un inhibidor de cinasas.Info
- Publication number
- MX2023010606A MX2023010606A MX2023010606A MX2023010606A MX2023010606A MX 2023010606 A MX2023010606 A MX 2023010606A MX 2023010606 A MX2023010606 A MX 2023010606A MX 2023010606 A MX2023010606 A MX 2023010606A MX 2023010606 A MX2023010606 A MX 2023010606A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- solid forms
- kinase inhibitor
- forms
- compound
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 3
- 239000007787 solid Chemical group 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 abstract 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen diversas formas de sales y formas sólidas de base libre del Compuesto (I) representado por la fórmula que sigue. (ver formula I) También se describen composiciones farmacéuticas que las comprenden, métodos de tratamiento de trastornos y afecciones que se asocian a alteraciones de PDGFRA y KIT de carácter oncogénico mediante el uso de ellas y métodos para elaborar las formas de sales del Compuesto (I) y formas cristalinas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159107P | 2021-03-10 | 2021-03-10 | |
| US202163208641P | 2021-06-09 | 2021-06-09 | |
| PCT/US2022/019776 WO2022192558A1 (en) | 2021-03-10 | 2022-03-10 | Salt and solid forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010606A true MX2023010606A (es) | 2023-10-19 |
Family
ID=81074313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010606A MX2023010606A (es) | 2021-03-10 | 2022-03-10 | Formas de sales y sólidas de un inhibidor de cinasas. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4305036A1 (es) |
| JP (1) | JP2024509276A (es) |
| KR (1) | KR20240013720A (es) |
| AU (1) | AU2022234314A1 (es) |
| BR (1) | BR112023018246A2 (es) |
| CA (1) | CA3211477A1 (es) |
| CR (1) | CR20230479A (es) |
| IL (1) | IL305791A (es) |
| MX (1) | MX2023010606A (es) |
| WO (1) | WO2022192558A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210293A1 (en) | 2019-04-12 | 2020-10-15 | Blueprint Medicines Corporation | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
-
2022
- 2022-03-10 JP JP2023555320A patent/JP2024509276A/ja active Pending
- 2022-03-10 AU AU2022234314A patent/AU2022234314A1/en active Pending
- 2022-03-10 BR BR112023018246A patent/BR112023018246A2/pt unknown
- 2022-03-10 MX MX2023010606A patent/MX2023010606A/es unknown
- 2022-03-10 IL IL305791A patent/IL305791A/en unknown
- 2022-03-10 KR KR1020237034550A patent/KR20240013720A/ko unknown
- 2022-03-10 WO PCT/US2022/019776 patent/WO2022192558A1/en active Application Filing
- 2022-03-10 EP EP22714289.0A patent/EP4305036A1/en active Pending
- 2022-03-10 CA CA3211477A patent/CA3211477A1/en active Pending
- 2022-03-10 CR CR20230479A patent/CR20230479A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023018246A2 (pt) | 2024-01-30 |
| KR20240013720A (ko) | 2024-01-30 |
| IL305791A (en) | 2023-11-01 |
| EP4305036A1 (en) | 2024-01-17 |
| CR20230479A (es) | 2024-03-08 |
| AU2022234314A1 (en) | 2023-09-28 |
| JP2024509276A (ja) | 2024-02-29 |
| WO2022192558A1 (en) | 2022-09-15 |
| CA3211477A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220354A (es) | Inhibidores de egfr | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
| MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
| TW200637539A (en) | CTGF inhibitors | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| TW200800990A (en) | Azaindole inhibitors of aurora kinases | |
| MX2009011579A (es) | Pirimidinonas como moduladores de caseina cinasa ii (ck2). | |
| MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
| WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
| SE0400284D0 (sv) | Novel compounds | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| EP4327827A3 (en) | Amorphous kinase inhibitor formulations and methods of use thereof | |
| MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
| SG162722A1 (en) | N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX2022006470A (es) | Tiromimeticos novedosos. | |
| MX2009011059A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
| MX2022005615A (es) | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo. | |
| MX2022000164A (es) | Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos. | |
| WO2020210481A8 (en) | Heterocyclic compounds as kinase inhibitors for therapeutic uses | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| MX2010005787A (es) | Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina. |